BMY

BRISTOL MYERS SQUIBB CO

Healthcare • USA

Apr 05 • 04:00PM ET
46.75
+0.94 (+2.05%)
Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphi ... read more

Full Time Employees 34,100
Phone 212 546 4000
Website https://www.bms.com
CEO Dr. Christopher S. Boerner Ph.D.
IPO Date 1972-06-01
Sector Healthcare
Industry Drug Manufacturers - General
Address 430 East 29th Street, New York, NY 10016
Balance Sheet
Total Cash $10,875,000,000
Total Debt $49,711,000,000
Current Ratio 1.28
Quick Ratio 0.94
Profitability
Gross Margin 70.47%
Net Margin 11.38%
ROE 31.16%
ROA 5.86%
ROIC 8.10%
Balance Sheet
Total Cash $10,875,000,000
Total Debt $49,711,000,000
Current Ratio 1.28
Quick Ratio 0.94
Profitability
Gross Margin 70.47%
Net Margin 11.38%
ROE 31.16%
ROA 5.86%
ROIC 8.10%
Name BRISTOL MYERS SQUIBB CO Sector Healthcare Currency USD Relative Volume 1.25 Market Cap 112221
Current Ratio 1.25 Dividend / Share 2.4 EPS -4.41 Revenue 48300000000 P/S 2.3
P/E -12.5 Beta -0.02 Income -8948000000 Volume 14637250 Average Volume 11710824
Distance to 200DMA 3.93% 200 DMA 53.21 50 DMA 58.74 ROA -9.4 ROE -53.4
Distance to 50DMA -5.86% Return 1Y 11.25% Return YTD -1.16% Forward PE Qtly Growth YOY
Debt/Eq 4.67 P/B 6.9 Dividend Yield 4.2% Net Margin -18.53% Payout Ratio -54.4
Performance
52 Week Range -54.4%
Distance to 200DMA 1.28%
Day Change Percent $0.60
Performance Week $0.6
Performance Month $0.6
Performance Quarter 2024-07-05
Performance YTD $0.6
Performance Year $0.6

Performance Range

Day

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Balance Sheet
Total Cash $7,890,000,000
Total Debt $49,752,000,000
Current Ratio 1.24%
Quick Ratio 0.84%
Profitability
Gross Margin 70.47%
Net Margin 11.38%
ROE 31.16%
ROA 5.86%
ROIC 8.10%
Valuation
Price to Earnings 17.51
Price to Book 5.46
Price to Sales 1.99
Price to Free Cash Flow 7.25
Dividends
Payout Ratio 90.62%
Dividend Yield 5.18%
Dividend Amount $0.60
Last Dividend Pay Date 2024-07-05
Last Dividend Paid $0.6
Performance
52 Week Range -54.4%
Distance to 200DMA 1.28%
Day Change Percent $0.60
Performance Week $0.6
Performance Month $0.6
Performance Quarter 2024-07-05
Performance YTD $0.6
Performance Year $0.6
Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphi ... read more

Full Time Employees 34,100
Phone 212 546 4000
Website https://www.bms.com
CEO Dr. Christopher S. Boerner Ph.D.
IPO Date 1972-06-01
Sector Healthcare
Address 430 East 29th Street, New York, NY 10016
Histogram - Daily

Balance Sheet
Total Cash $7,890,000,000
Total Debt $49,752,000,000
Current Ratio 1.24%
Quick Ratio 0.84%
Profitability
Gross Margin 0.7490%
Net Margin -0.1530%
ROE -0.36%
ROA -0.08%
Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphi ... read more

Full Time Employees 34,100
Phone 212 546 4000
Website https://www.bms.com
CEO Dr. Christopher S. Boerner Ph.D.
IPO Date 1972-06-01
Sector Healthcare
Address 430 East 29th Street, New York, NY 10016
Monthly Win Rate

Balance Sheet (Multi-Column Example)
Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023
Cash & Short Term Investments 53,775.0 65,171.0 61,801.0 67,150.0 73,100.0 61,555.0 62,482.0 55,872.0
Receivables 59,306.0 66,243.0 43,172.0 41,150.0 50,102.0 60,985.0 39,186.0 35,899.0
Inventory 6,911.0 7,286.0 6,165.0 6,232.0 6,511.0 6,331.0 7,351.0 7,482.0

Latest News

Final Trade: RIO, FCX, X, BMY
Final Trade: RIO, FCX, X, BMY

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

2025-05-15 18:27:28 - youtube.com
Income Alert: 2 Bargain Blue Chips, Up To 8% Yield
Income Alert: 2 Bargain Blue Chips, Up To 8% Yield

The S&P 500's dividend yield sits near a historical low, making undervalued individual stocks far more appealing. Bristol Myers Squibb offers a 5.3% yield and trades at a low PE of 6.8, with strong pr

2025-05-13 08:00:00 - seekingalpha.com
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t

2025-05-12 12:30:03 - seekingalpha.com
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Pressure is still on the pharma sector, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.

2025-05-08 19:23:04 - youtube.com
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

2025-05-08 10:40:54 - zacks.com
Dividend Harvesting Portfolio Week 218: $21,800 Allocated, $2,195.04 In Projected Dividends
Dividend Harvesting Portfolio Week 218: $21,800 Allocated, $2,195.04 In Projecte

Earnings season saw strong reports from Microsoft, Apple, Meta, and Amazon, boosting the S&P 500 by 2.75% and the Nasdaq by 2.82%. The Dividend Harvesting Portfolio gained 1.98% this week, with a tota

2025-05-08 09:00:00 - seekingalpha.com
Bristol Myers to invest $40 billion in the US over 5 years, CEO says
Bristol Myers to invest $40 billion in the US over 5 years, CEO says

Bristol Myers Squibb will spend $40 billion in the US over the next five years, CEO Christopher Boerner wrote in an opinion piece published by Stat News on Monday.

2025-05-05 17:23:58 - reuters.com
First-Quarter GDP Halfway to Recession: Move to These Safe High-Yield Dividend Stocks Now
First-Quarter GDP Halfway to Recession: Move to These Safe High-Yield Dividend S

The first report for U.S. gross domestic product (GDP) came in at –0.3% as the economy contracted for the first time in three years.

2025-05-01 07:15:05 - 247wallst.com
This High-Yield Pharma Stock Looks Like an Incredible Bargain
This High-Yield Pharma Stock Looks Like an Incredible Bargain

When markets get choppy, smart investors often seek refuge in pharmaceutical stocks. These companies typically offer consistent cash flows, essential products, and solid dividends regardless of econom

2025-04-30 06:45:00 - fool.com
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

2025-04-29 10:00:48 - zacks.com
BMY Falls 4% Post Q1 Earnings: Should You Buy, Sell or Hold the Stock?
BMY Falls 4% Post Q1 Earnings: Should You Buy, Sell or Hold the Stock?

Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay on the sidelines as generic competition for legacy drugs and recent pipelin

2025-04-28 10:20:38 - zacks.com
Top 3 Health Care Stocks That May Rocket Higher In April
Top 3 Health Care Stocks That May Rocket Higher In April

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

2025-04-28 07:16:34 - benzinga.com
Retirement Strategy: 2 Blue Chip Dividends Now Way Too Cheap
Retirement Strategy: 2 Blue Chip Dividends Now Way Too Cheap

Earnings season offers opportunities to buy undervalued blue-chip stocks like Verizon and Bristol Myers Squibb, both yielding 5-7% and trading below historical PE ratios. Verizon's growth in 5G, broad

2025-04-28 07:15:00 - seekingalpha.com
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off

It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong un

2025-04-26 18:05:00 - fool.com
5 Positives From Bristol-Myers Squibb's Q1 2025 Results
5 Positives From Bristol-Myers Squibb's Q1 2025 Results

Bristol-Myers Squibb's Q1 2025 results confirm that the stock has significant potential upside now. The company's Growth Portfolio showed healthy sales increase, while the non-GAAP EPS surprised posit

2025-04-25 10:27:06 - seekingalpha.com